Explore our premier inventory of high-purity active pharmaceutical ingredients (APIs) and dermatological intermediates manufactured under strict ISO/GMP quality standards.
Perioral Dermatitis (POD) represents an inflammatory dermatosis characterized by micropapules, microvesicles, and erythematous scaling around the perioral, perinasal, and periocular zones. Traditional interventions often rely heavily on topical calcineurin inhibitors or systemic tetracyclines. However, recent clinical guidelines emphasize micronized Azelaic Acid (15%–20%) as a cornerstone first-line non-steroidal therapy, especially for patients exhibiting steroid-induced rebound flares or cutaneous hyper-reactivity.
Azelaic acid suppresses neutrophil-generated reactive oxygen species (ROS) and downregulates pro-inflammatory cytokines including IL-1β, IL-6, and TNF-α. It directly targets the kallikrein-5 (KLK5) and cathelicidin (LL-37) pathway responsible for papulopustular lesions.
Exerts broad-spectrum bacteriostatic action against opportunistic cutaneous flora (*Propionibacterium acnes*, *Staphylococcus epidermidis*) without inducing bacterial resistance or disrupting the delicate lipid mantle of perioral skin.
Inhibits follicular hyperkeratosis by reducing filaggrin synthesis and normalizing epidermal differentiation. Prevents microcomedone formation and follicular occlusion in perioral hair follicles.
| Active Ingredient (API) | Primary Efficacy Mechanism | Steroid Rebound Risk | Long-term Tolerability | Formulation Stability Requirements |
|---|---|---|---|---|
| Azelaic Acid (15%-20%) | ROS Scavenging, KLK5/LL-37 Suppression, Follicular Normalization | Zero (Non-Steroidal) | Excellent (Minimal barrier disruption) | Suspension / Micro-emulsion, pH 4.0 - 5.5 |
| Metronidazole (0.75%-1%) | Imidazolyl anti-protozoal & anti-inflammatory reduction | Zero | Moderate (Risk of localized dryness) | Solubilized system, light sensitive |
| Topical Corticosteroids | Immune suppression (Transient vasoconstriction) | High (Primary Cause of Chronic POD) | Poor (Epidermal atrophy, telangiectasia) | Anhydrous ointment / O/W Cream |
| Ivermectin (1%) | Anti-parasitic (*Demodex* reduction) & anti-inflammatory | Zero | Good | Emulgel systems |
As a leading Chinese chemical raw material manufacturer, JIMPOCHEM produces ultra-pure Azelaic Acid API specifically refined for pharmaceutical topical formulations and dermatological cosmeceuticals targeting sensitive perioral conditions. Our micro-milled grades ensure zero gritty sensation, optimal dermal bio-availability, and absolute chemical stability.
≥ 99.5%
Ultra-low related substance profile complying with USP/EP standards.
< 5.0 μm
Micronized powder for non-irritating, silky perioral topical creams.
106.5°C - 109°C
Consistent crystalline thermodynamic profile for predictable formulation.
< 5.0 ppm
Rigorously tested via ICP-MS to protect compromised barrier skin.
JIMPOCHEM CO., LTD was established in 2010 and is headquartered in the Chemical Industry Park of Jinan City, Shandong Province. Spanning over 500 acres, the company is a professional chemical raw material manufacturer integrating R&D, large-scale production, global sales, and dedicated technical services. We specialize in high-end fine chemicals, active pharmaceutical ingredients (APIs), and cosmetic raw materials.
Leveraging direct raw material channels and bio-based oleic acid oxidation technology, we maintain an annual capacity exceeding 5,000 metric tons of Azelaic Acid API. Automated digital control balances bulk commercial lots with flexible custom micronization orders.
Every batch undergoes 100% itemized inspection. Our ISO 9001 and ISO 14001 certified quality control systems allow buyers to trace raw material origins, process parameters, HPLC chromatograms, and batch lot numbers via digital CoAs.
Aligned with global dual-carbon mandates, our zero-ozone catalytic oxidation pathway minimizes VOC emissions and recycles wastewater. downstream brand owners meet stringent European eco-labeling standards seamlessly.
Navigating international regulatory frameworks for Azelaic Acid perioral dermatitis products requires deep compliance expertise. JIMPOCHEM provides localized dossier packages, regulatory filings (EU CPNP, US FDA MoCRA, China NMPA), and customized formulation troubleshooting.
We provide complete technical documentation to expedite your regional market access:
Incorporating Azelaic Acid into stable micro-emulsions can be challenging due to its high melting point and limited solubility. Our technical team assists formulators with:
Take an insider look at our modern chemical production base, advanced R&D laboratories, and automated packaging lines in Jinan City, Shandong Province.
Modern production zone covering over 500 acres built to rigorous environmental standards.
Industry pioneer in micro-milled Azelaic Acid and high-end cosmetic intermediates.
Dedicated team providing formula optimization, trial batches, and scale-up services.
The demand for Azelaic Acid is expanding beyond clinical dermatology into mainstream cosmeceuticals, high-performance acne therapy, and sensitive skin barrier restoration products. Market intelligence predicts a CAGR of 7.2% through 2030, driven by the global surge in steroid-free perioral dermatitis treatments.
Formulated into leave-on serums, anti-redness emulsions, perioral barrier creams, and clarifying face cleansers targeting post-inflammatory hyperpigmentation (PIH).
Serving as the core active ingredient in FDA-approved 15% gel and 20% topical creams for perioral dermatitis, papulopustular rosacea, and severe acne vulgaris.
Utilized in high-performance polymer synthesis, specialty plasticizers, and industrial lubricants where linear dicarboxylic acid structures are required.
Browse our extended catalog of high-purity organic compounds, preservatives, and skin conditioning agents available for global bulk supply.
JIMPOCHEM
